Symbollon Initiates Sales of IoGen Through Web Site BuyIoGen.com

• Press Release
• Source: Symbollon Pharmaceuticals, Inc.
• On 11:53 am EST, Wednesday November 19, 2008

FRAMINGHAM, MA--(MARKET WIRE)--Nov 19, 2008 -- Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) is pleased to announce that it has initiated retail sales of IoGen(TM), its dietary supplement for women's breast health, through its web site, www.BuyIoGen.com. IoGen is the first dietary supplement formulated to promote breast health for women. IoGen can be purchased in 2 month (60 tablets) and 4 month (120 tablets) quantities.

Related Quotes

Symbol	Price	Change
SYMBA.OB	0.05	0.00

{"s" : "symba.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

"We are pleased to make IoGen available to women through our web site, www.BuyIoGen.com," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. "IoGen is the first dietary supplement designed to promote breast health. We believe that IoGen addresses a significant need for women concerned about improving their breast health. We continue to pursue additional retail distribution channels for IoGen."

About Symbollon Pharmaceuticals, Inc. (OTC BB:SYMBA.OB - News) is a specialty pharmaceutical company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.

Forward-Looking Statement

This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to successfully commercial of IoGen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) management and the Board of Directors will be able to maximize shareholder value by leveraging the Company's proprietary technology, and (v) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.

     CONTACT:
     Paul C. Desjourdy
     President and CEO
     Symbollon Pharmaceuticals, Inc.
     (508) 620-7676, x202
     http://www.symbollon.com